These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11891954)

  • 1. Pilot trial of concomitant chemotherapy with paclitaxel and split-course radiotherapy for very advanced squamous cell carcinoma of head and neck.
    Feher O; Martins SJ; Lima CA; Salvajoli JV; Simpson AJ; Kowalski LP
    Head Neck; 2002 Mar; 24(3):228-35. PubMed ID: 11891954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck.
    Varveris H; Mazonakis M; Vlachaki M; Kachris S; Lyraraki E; Zoras O; Maris T; Froudarakis M; Velegrakis J; Perysinakis C; Damilakis J; Samonis G
    Oncol Rep; 2003; 10(1):185-95. PubMed ID: 12469168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Meluch AA; McClurkan S; Gray JR; Stroup SL; Burris HA; Yardley DA; Bradof JE; Yost K; Ellis JK; Greco FA
    Cancer J; 2002; 8(4):311-21. PubMed ID: 12184409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Final report of a pilot trial of accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel for locally advanced head and neck cancer.
    Bucci MK; Rosenthal DI; Hershock D; Metz J; Devine P; Kligerman MM; Machtay M
    Am J Clin Oncol; 2004 Dec; 27(6):595-602. PubMed ID: 15577438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer.
    Sunwoo JB; Herscher LL; Kroog GS; Thomas GR; Ondrey FG; Duffey DC; Solomon BI; Boss C; Albert PS; McCullugh L; Rudy S; Muir C; Zhai S; Figg WD; Cook JA; Mitchell JB; Van Waes C
    J Clin Oncol; 2001 Feb; 19(3):800-11. PubMed ID: 11157034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy.
    Langer CJ; Duffy K; Horwitz EM; Litwin S; Rosvold E; Schol J; Keenan E; Nicolaou N; Friedman CD; Ridge JA
    Cancer Invest; 2006 Mar; 24(2):164-73. PubMed ID: 16537186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol.
    Abitbol A; Abdel-Wahab M; Lewin A; Troner M; Rodrigues MA; Hamilton-Nelson KL; Markoe A
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):942-7. PubMed ID: 12095561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
    Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
    Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction paclitaxel in previously untreated, resectable, advanced squamous cell carcinomas of head and neck.
    Grecula JC; Smith RE; Rhoades CA; Sharma P; Agrawal A; Zhang H; Allen J; Goldman FP; Young D; Schuller DE
    Cancer; 2000 Dec; 89(12):2587-96. PubMed ID: 11135220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of 96-hour paclitaxel infusion plus accelerated radiotherapy of unrespectable head and neck cancer.
    Machtay M; Aviles V; Kligerman MM; Treat J; Weinstein GS; Weber RS; Mirza N; Chalian AA; Rosenthal DI
    Int J Radiat Oncol Biol Phys; 1999 May; 44(2):311-5. PubMed ID: 10760424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma.
    Amrein PC; Clark JR; Supko JG; Fabian RL; Wang CC; Colevas AD; Posner MR; Deschler DG; Rocco JW; Finkelstein DM; McIntyre JF
    Cancer; 2005 Oct; 104(7):1418-27. PubMed ID: 16116597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck.
    Rosenthal DI; Lee JH; Sinard R; Yardley DA; Machtay M; Rosen DM; Egorin MJ; Weber RS; Weinstein GS; Chalian AA; Miller LK; Frenkel EP; Carbone DP
    J Clin Oncol; 2001 Mar; 19(5):1363-73. PubMed ID: 11230480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck.
    Suntharalingam M; Haas ML; Van Echo DA; Haddad R; Jacobs MC; Levy S; Gray WC; Ord RA; Conley BA
    Cancer; 2001 Feb; 91(3):548-54. PubMed ID: 11169937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck.
    Suntharalingam M; Haas ML; Conley BA; Egorin MJ; Levy S; Sivasailam S; Herman JM; Jacobs MC; Gray WC; Ord RA; Aisner JA; Van Echo DA
    Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):49-56. PubMed ID: 10758304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer.
    Agarwala SS; Cano E; Heron DE; Johnson J; Myers E; Sandulache V; Bahri S; Ferris R; Wang Y; Argiris A
    Ann Oncol; 2007 Jul; 18(7):1224-9. PubMed ID: 17675395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes and toxicity of concurrent paclitaxel and radiotherapy for locally advanced head-and-neck cancer.
    Citrin D; Mansueti J; Likhacheva A; Sciuto L; Albert PS; Rudy SF; Cooley-Zgela T; Cotrim A; Solomon B; Colevas AD; Russo A; Morris JC; Herscher L; Smith S; Van Waes C
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1040-6. PubMed ID: 19117692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of radiotherapy and simultaneous 24-hour paclitaxel in patients with locally advanced head and neck squamous cell carcinoma.
    Steinberg L; Hassan M; Olmsted L; Sharan V; Stepnick D; Hoppel C; Mugharbil A; Subramanyan S; McGloin B; Mackay W; Strauss M
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-51-S19-56. PubMed ID: 9427267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.
    Langer CJ; Harris J; Horwitz EM; Nicolaou N; Kies M; Curran W; Wong S; Ang K
    J Clin Oncol; 2007 Oct; 25(30):4800-5. PubMed ID: 17947728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperfractionated or Accelerated Hyperfractionated Re-irradiation with ≥42 Gy in Combination with Paclitaxel for Secondary/Recurrent Head-and-Neck Cancer.
    Rades D; Bartscht T; Idel C; Schild SE; Hakim SG
    Anticancer Res; 2018 Jun; 38(6):3653-3656. PubMed ID: 29848723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.